While a combination of chemotherapy drugs can sometimes cure diffuse B-cell lymphoma or follicular lymphoma, the cancer does return in some cases. Paul Hamlin, Clinical Director of Memorial Sloan Kettering’s Outpatient Lymphoma Service, describes a randomized phase III clinical trial to test the ability of the drug ibritumomab tiuxetan versus observation alone (no treatment) for reducing the risk of this cancer returning in patients aged 60 and older who have been in remission. He talks about the design of the trial, how the drug works, and who is eligible to participate.
A Phase III Study of Ibritumomab Tiuxetan versus Observation in Older Patients with Diffuse Large B-Cell Lymphoma in Remission following R-CHOP
Hamlin, Paul, MD